Polaryx Therapeutics, Inc. (PLYX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$3.1M
Cash & Equivalents
$2.1M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$116M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

DateEventDrug
2026-12-31 Phase3 Readout —

FDA-Related SEC Filings

DateTypeDescriptionLink
2026-05-28 8-K Polaryx Therapeutics, Inc. (PLYX) (CIK 0002075320) - PRESS RELEASE DATED MAY 28, 2026 EDGAR

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for PLYX.

SEC EDGAR Filings

All SEC filings for Polaryx Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.